Provided by Tiger Trade Technology Pte. Ltd.

Addex Therapeutics Ltd

2.76
-0.1900-6.44%
Pre-market: 2.950.1900+6.88%04:01 EDT
Volume:5K
Turnover:14.62K
Market Cap:4.84M
PE:-0.30
High:2.91
Open:2.91
Low:2.67
Close:2.95
52wk High:11.97
52wk Low:2.56
Shares:1.75M
Float Shares:1.57M
Volume Ratio:0.17
T/O Rate:0.34%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-9.2978
EPS(LYR):-9.4830
ROE:-150.58%
ROA:-27.12%
PB:2.12
PE(LYR):-0.29

Loading ...

NASDAQ Trade Halt Volatility Trading Pause at 11:24 Am

Reuters
·
Sep 28

Press Release: Addex Therapeutics Reports 2026 Half-Year Results and Provides Corporate Update

Dow Jones
·
Sep 28

Press Release: Addex Therapeutics to Report 2026 Half-Year Financial Results and Host Conference Call on September 28, 2026

Dow Jones
·
Sep 24

Press Release: ADDEX Raises USD 2.8 Million Through Its ATM Agreement and Extends Cash Runway to the Fourth Quarter 2027

Dow Jones
·
Aug 26

NASDAQ Trade Halt Volatility Trading Pause at 02:50 Pm

Reuters
·
Aug 21

Addex Therapeutics announces publication of new ADX71743 preclinical research

TIPRANKS
·
Jul 08

Press Release: Addex Announces Publication of Research Highlighting Therapeutic Potential of Mglu7 Modulation in Regulating Sleep and Wakefulness

Dow Jones
·
Jul 08

Press Release: Addex Shareholders Approve All Resolutions at Annual General Meeting

Dow Jones
·
Jun 30

Addex Therapeutics Reports Q1 2026 Net Loss Of CHF 1.71M Versus CHF 1.47M A Year Ago, Cash CHF 0.9M

Benzinga Earnings
·
Jun 25

Press Release: Addex Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Dow Jones
·
Jun 25

Press Release: Addex Therapeutics to Report 2026 First Quarter Financial Results and Host Conference Call on June 25, 2026

Dow Jones
·
Jun 22

Press Release: Addex Convenes Annual General Meeting 2026

Dow Jones
·
Jun 05

Addex Closes 2025 With CHF 6.7M Net Loss And CHF 1.6M Cash, Regains ADX71149 Rights And Invests In Stalicla

Benzinga Earnings
·
Apr 30

Press Release: Addex Reports Full Year 2025 Financial Results and Provides Corporate Update

Dow Jones
·
Apr 30

Addex Therapeutics announces GABAB PAM candidate data

TIPRANKS
·
Apr 29

Press Release: Addex GABAB PAM Candidate Demonstrates Solid Anti-Tussive Activity in Bleomycin IPF-Related Chronic Cough Model

Dow Jones
·
Apr 29

Addex Therapeutics says spin-out company to complete NTX-253 study in Q2

TIPRANKS
·
Apr 23

Press Release: Addex Spin-Out Company Neurosterix on Track to Complete Phase 1 Clinical Study of NTX-253 for Schizophrenia in Q2 2026

Dow Jones
·
Apr 23

Press Release: Addex GABAB PAM Candidate Demonstrates Robust Anti-Tussive Activity in Non-Human Primate Chronic Cough Model

Dow Jones
·
Apr 21